Global Retirement Partners LLC Acquires New Shares in Boston Scientific Corporation $BSX

Key Points

• Global Retirement Partners initiated a Boston Scientific position worth approximately $1.61 million, while institutional investors collectively own 89.07% of the company.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $71.62, despite several recent target-price reductions.
• Boston Scientific exceeded quarterly earnings and revenue expectations, and its board authorized a $5 billion share-repurchase program covering up to 6.4% of outstanding shares.

Global Retirement Partners LLC acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 37,710 shares of the medical equipment provider's stock, valued at approximately $1,609,000.

A number of other institutional investors also recently bought and sold shares of the company. Kelleher Financial Advisors acquired a new stake in Boston Scientific in the 2nd quarter valued at about $25,000. FWL Investment Management LLC purchased a new position in Boston Scientific during the 2nd quarter valued at about $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of Boston Scientific in the first quarter valued at about $28,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BSX has been the topic of a number of recent research reports. Bank of America reduced their target price on Boston Scientific from $105.00 to $68.00 and set a "buy" rating on the stock in a research note on Monday, May 18th. Robert W. Baird set a $56.00 price target on Boston Scientific in a report on Thursday, July 30th. Argus restated a "hold" rating on shares of Boston Scientific in a research report on Friday, July 31st. Needham & Company LLC decreased their price objective on Boston Scientific from $77.00 to $57.00 and set a "buy" rating on the stock in a research note on Wednesday, July 8th. Finally, Canaccord Genuity Group dropped their price objective on Boston Scientific from $70.00 to $66.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $71.62.

Boston Scientific Trading Down 0.7%

Shares of BSX stock opened at $51.46 on Tuesday. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The firm's 50-day simple moving average is $46.12 and its 200-day simple moving average is $58.81. The firm has a market cap of $74.58 billion, a P/E ratio of 20.83, a PEG ratio of 1.13 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific's revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's leadership believes its stock is undervalued.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig acquired 5,000 shares of the business's stock in a transaction dated Friday, July 31st. The shares were bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Cheryl Pegus bought 1,770 shares of the company's stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 202,122 shares of company stock valued at $9,813,931. Corporate insiders own 0.34% of the company's stock.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source